PR Newswire Clinical TrialsOriginal article
Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment
Phase 2CBL-514CBL-0201WRtirzepatidePositive
AI Analysis
Summary
Caliway received FDA IND clearance for CBL-0201WR, a Phase 2 trial evaluating CBL-514 in combination with tirzepatide, and obtained IRB approval to initiate enrollment in the pivotal Phase 3 trial SUPREME-01.
Clinical Trial Data
Phase
2
Outcome Details
IND clearance for CBL-0201WR Phase 2 trial and IRB approval for pivotal Phase 3 trial SUPREME-01 initiation
Importance:6/10
Sentiment:
0.70
FDA IND clearancePhase 2 trialPhase 3 trialcombination therapySUPREME-01
Read the original article
Published by PR Newswire Clinical Trials on August 26, 2026 1:24 AM